RxDoctor Payments Data

Malak Isaac, MD

Family Medicine · Centreville, VANPI 1922130228

Payments from drug & device makers

$1,817in general payments, 2019–2025

Across 96 payments — averaging $18.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$451
  • Pfizer$288
  • AstraZeneca$255
  • Novo Nordisk$249
  • Novartis$147
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$108
  • plus $318 from 8 others

What the payments were for

  • Food & beverage$1,80399%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,817 in reported general payments places this provider in the 75th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$197,128
Medicare patients
187
Services billed
1,788

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide53$77,993
FarxigaDapagliflozin Propanediol62$71,136
Repatha SureclickEvolocumab58$57,275
XareltoRivaroxaban37$47,246
MyrbetriqMirabegron35$41,425
ProliaDenosumab18$31,831
EliquisApixaban22$29,945
TradjentaLinagliptin23$25,350
MounjaroTirzepatide21$21,867
JardianceEmpagliflozin12$19,221
JanuviaSitagliptin Phosphate19$18,149
Repatha SyringeEvolocumab11$18,005
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$16,027
Praluent PenAlirocumab11$15,184
Rosuvastatin Calcium281$4,865

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$249$77,99353 claims
AstraZenecaFarxiga$255$71,13662 claims
Astellas Pharma US IncMyrbetriq$20$41,42535 claims
AmgenProlia$451$31,83118 claims
PfizerEliquis$288$29,94522 claims
Lilly USA, LLCMounjaro$107$21,86721 claims
MerckJanuvia$20$18,14919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Centreville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →